OncoMatch/Clinical Trials/NCT07258407
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Is NCT07258407 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies TD001 for metastatic castration-resistant prostatic cancer.
Treatment: TD001 — This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 expression
Disease stage
Metastatic disease required
Prior therapy
Must have received: androgen receptor pathway inhibitor
Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) drug
Must have received: androgen deprivation therapy
Prior orchiectomy and/or ongoing androgen deprivation therapy
Cannot have received: (strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223)
Exception: within 6 months before treatment
Previous treatment with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body irradiation, within 6 months before treatment
Cannot have received: systemic anticancer therapy
Exception: within 28 days before treatment
Systemic anticancer therapy including an investigational agent within 28 days before treatment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University, Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify